Drug-Related Problems in the Neonatal and Pediatric Intensive Care Units: Incidence, Predictors, and Impact of Clinical Pharmacist Interventions
International Journal of Drug Delivery Technology · 05.05.2026 · 16 (24s)
DOI: 10.25258/ijddt.16.24s.43 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 05.05.2026. Verfasst von Diksha S Kempannavar und 4 weiteren Autor:innen.
Themen: Intensivpflege
Abstract (Originalsprache)
Background
Drug-related problems (DRPs) pose a significant risk to critically ill neonates and children due to polypharmacy, off-label drug use and immature pharmacokinetics. However standardized comparative data across both the Neonatal and Pediatric Intensive Care Unit (NICU & PICU) remain scarce in tertiary care settings.
Objective
To identify, classify and evaluate DRPs in the NICU and PICU using the Pharmaceutical Care Network Europe (PCNE) classification v9.1; to assess incidence, causes, and independent predictors; to document pharmacist intervention acceptance and DRP resolution rates.
Methods
A 6-month prospective interventional study enrolled 286 patients (NICU: n=67; PICU: n=219) at a tertiary care teaching hospital in India. DRPs were identified through daily medication review, classified using PCNE v9.1 and pharmacist-led interventions were proposed with acceptance and resolution outcomes documented. Independent predictors were identified using multivariable binary logistic regression.
Results
A total of 168 DRPs were identified (NICU-43; PICU-125) with treatment ineffectiveness and adverse drug events predominating in the NICU and treatment effectiveness and safety issues in PICU. Drug selection errors were the leading cause in both units. Of 195 pharmacist interventions proposed, the acceptance rates were 95.3% (NICU) and 93.4% (PICU), with resolution rates of 76.7% and 88.8% respectively. The number of prescribed drugs was the sole independent predictor of DRPs in both units.
Conclusion
DRPs are prevalent in critically ill neonates and children, with polypharmacy as the sole independent risk factor. High pharmacist intervention acceptance and resolution rates support integration of clinical pharmacists into intensive care teams though the single-center design, limited study duration and exclusion criteria may restrict generalisability.
Zitieren
APA
Kempannavar, D. S., Hulikatti, M. A., Naduvinamani, P. R., Tuppad, P. O., & Wali, S. C. (2026). Drug-Related Problems in the Neonatal and Pediatric Intensive Care Units: Incidence, Predictors, and Impact of Clinical Pharmacist Interventions. International Journal of Drug Delivery Technology, 16(24s). https://doi.org/10.25258/ijddt.16.24s.43
Vancouver
Kempannavar DS, Hulikatti MA, Naduvinamani PR, Tuppad PO, Wali SC. Drug-Related Problems in the Neonatal and Pediatric Intensive Care Units: Incidence, Predictors, and Impact of Clinical Pharmacist Interventions. International Journal of Drug Delivery Technology. 2026;16(24s). doi:10.25258/ijddt.16.24s.43
BibTeX
@article{Kempannavar2026,
author = {Kempannavar, Diksha S and Hulikatti, Misba A and Naduvinamani, Pooja R and Tuppad, Prajwal O and Wali, Shashikala C},
title = {Drug-Related Problems in the Neonatal and Pediatric Intensive Care Units: Incidence, Predictors, and Impact of Clinical Pharmacist Interventions},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {24s},
doi = {10.25258/ijddt.16.24s.43}
}
EUVIMED